FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention is aimed at compound in accordance with formula (R2R3)-B1-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-A11-A12-A13-B2-B3-R1, which act as ligands for one or several melanocortin receptors, their pharmaceutically acceptable salts.
EFFECT: elaboration of method of peptide application and obtaining pharmaceutical compositions, which include said peptides.
132 cl, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF MELANOCORTIN FOR TREATING INSULIN SENSITIVITY | 2008 |
|
RU2453328C2 |
| METHOD FOR TREATMENT OF DISORDERS ASSOCIATED WITH MELANOCORTIN 4 RECEPTOR PATH | 2016 |
|
RU2785889C1 |
| MELANOCORTIN RECEPTOR LIGANDS | 2006 |
|
RU2439079C2 |
| MELANOCORTIN RECEPTOR LIGANDS | 2006 |
|
RU2380372C2 |
| ALPHA- AND GAMMA-MSH ANALOGUES | 2013 |
|
RU2668791C2 |
| PEPTIDIC INTERLEUKIN-23 RECEPTOR INHIBITORS FOR ORAL ADMINISTRATION AND USE THEREOF FOR TREATING INFLAMMATORY INTESTINAL DISEASES | 2015 |
|
RU2736637C2 |
| PRODRUG COMPOSITIONS WITH HIGH DEGREE OF PENETRATION BASED ON PEPTIDES AND RELATED COMPOUNDS | 2010 |
|
RU2627065C2 |
| KV1_3 BLOCKERS | 2020 |
|
RU2825633C1 |
| PEPTIDE VECTORS | 2004 |
|
RU2361876C2 |
| PEPTIDE COMPOSITIONS | 2014 |
|
RU2725150C2 |
